A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD)
CLN-049-002
Phase 1 other active
Quick answer
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) for Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) is a Phase 1 program (other) at Cullinan Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cullinan Therapeutics
- Indication
- Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)
- Phase
- Phase 1
- Modality
- other
- Status
- active